Dr. Behnoush Salehi, CEO of the knowledge-based company Soroush Mana Pharmed, announced that the company’s new pharmaceutical manufacturing facility located in Alborz Province, is expected to be fully operational by the end of 2025.
According to the Public Relations Office of Golrang Pharmaceutical Group, Soroush Mana Pharmed, a subsidiary of Golrang Pharmaceutical Investment Group, currently produces 32 active pharmaceutical ingredients (APIs), 7 of which are officially certified as knowledge-based products by national regulatory authorities.
Expanding API and Finished Product Capabilities
In addition to its API portfolio, the company has already introduced three finished dosage forms (tablets and capsules) to the market and is planning to further expand its product line of finished pharmaceuticals.
Dr. Salehi emphasized that Soroush Mana Pharmed holds exclusive manufacturing rights for several critical APIs in Iran, including Tetrabenazine, Duloxetine, and Repaglinide—key compounds widely used in the treatment of neurological, psychiatric, and metabolic disorders.
A Strategic Manufacturing Site
The new production site, currently under construction in Eshtehard Industrial Zone, has reached 50% completion. It is designed to enhance the company’s production capacity, comply with international pharmaceutical standards, and support both domestic demand and export expansion.
International Market Reach
In the past year, the company achieved USD 500,000 in exports to Russia and India, underscoring its growing presence in international pharmaceutical markets. “Our strategic goal is to position Soroush Mana Pharmed as a leading API supplier in both the domestic and global pharmaceutical industries,” said Dr. Salehi.
With this major infrastructure expansion, Soroush Mana Pharmed aims to play a critical role in strengthening Iran’s pharmaceutical supply chain, reducing dependency on imported raw materials, and contributing to the country’s pharmaceutical self-sufficiency.
